NexImmune
22 articles with NexImmune
-
NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
2/16/2023
NexImmune, Inc. announced that new positive, preclinical data will be presented in an abstract titled “Prior Antigen Exposure Enhances the T cell Response to Bispecific T cell Engager Therapy” at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place on February 15-19, 2023 in Orlando, Florida.
-
NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company’s AIM Platform to Treat Viral Diseases
1/18/2023
NexImmune, Inc. (Nasdaq: NEXI) today announced the publication of an article highlighting the Company’s AIM platform as a new immunotherapy approach for viral diseases in Frontiers in Medicine.
-
NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update
11/14/2022
NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today reported financial results for the third quarter of 2022 and announced a change in corporate strategy.
-
NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)
10/6/2022
NexImmune, Inc. today announced a collaboration with the National Institute of Neurological Disorders and Stroke (NINDS), a division of the U.S. National Institutes of Health (NIH).
-
NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/9/2022
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference.
-
Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
9/8/2022
Selexis SA and NexImmune Inc. announced that they have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients.
-
NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers
8/15/2022
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today reported financial results for the second quarter of 2022.
-
NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers
7/14/2022
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, has received IND clearance for the Company’s first cellular therapy product candidate addressing solid tumors.
-
NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates
5/12/2022
NexImmune, Inc. reported financial results for the first quarter of 2022.
-
NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes
5/10/2022
NexImmune, Inc., Yale and JDRF have begun a two-year project to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.
-
NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors
5/10/2022
NexImmune, Inc. (Nasdaq: NEXI), today announced the appointment of Leena Gandhi, M.D., Ph.D., Director for the Center of Therapeutic Innovation at Dana-Farber Cancer Institute, to its Board of Directors as a Non-Executive Director.
-
NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center
4/26/2022
NexImmune, Inc. today announced a preclinical research collaboration with Columbia University Irving Medical Center’s (CUIMC) Herbert Irving Comprehensive Cancer Center (HICCC).
-
NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer
4/14/2022
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Mathias Oelke, Ph.D., has been promoted to Chief Scientific Officer.
-
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
3/17/2022
NexImmune, Inc. and Zephyr AI announced a strategic partnership focusing on the discovery and validation of novel targets for new T-cell-mediated therapies in oncology.
-
NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center
3/14/2022
NexImmune, Inc. today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center and part of NYU Langone Health.
-
NexImmune to Present at the Barclays 2022 Global Healthcare Conference
3/10/2022
NexImmune, Inc. announced that Kristi Jones, Chief Executive Officer, will present at the Barclays 2022 Global Healthcare Conference on Thursday, March 17, 2022 at 8:30 a.m. Eastern Time.
-
NexImmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
3/9/2022
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its fourth quarter and full year financial results for the full year 2021.
-
NexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of Directors
2/17/2022
NexImmune, Inc. announced that Kristi Jones has been appointed as the Company’s Chief Executive Officer and a member of its Board of Directors.
-
NexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrine Tumor Targets
2/1/2022
NexImmune, Inc. today announced a collaboration with Rutgers, The State University of New Jersey.
-
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.